Citations

Mayo Clinic

Showing 10 of 108523 citations.

Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma
Vizcaíno, M. Adelita , Nguyen, Aivi T. , Trejo‐Lopez, Jorge , Jenkins, Sarah M. , Jenkins, Robert B. , Mendoza, Cinthya J. Zepeda, Trejo-Lopez, Jorge A, Zepeda Mendoza, Cinthya J, Nguyen, Aivi T , Giannini, Caterina , Vaubel, Rachael A. , Raghunathan, Aditya , Zepeda‐Mendoza, Cinthya

Journal of Neuropathology & Experimental Neurology | July 24, 2024 | Volume: 83 | Issue: 12 | Pages: 1003-1009

10.1093/jnen/nlae076 | PMID 39042515 Get It

Abstract Pleomorphic xanthoastrocytomas (PXAs) harbor CDKN2A homozygous deletion in >90% of cases, resulting in loss of p16 expression by immunohistochemistry. Considering the proximity of MTAP to CDKN2A and their frequent concurrent deletions, loss of MTAP expression may be a surrogate for CDKN2A homozygous deletion. We evaluated p16 and MTAP expression in 38 patient PXAs (CNS WHO grade 2: n = 23, 60.5%; grade 3: n = 15, 39.5%) with available chromosomal microarray data to determine whether MTAP can be utilized independently or in combination with p16 to predict CDKN2A status. CDKN2A, CDKN2B, and MTAP homozygous deletion were present in 37 (97.4%), 36 (94.7%), and 25 (65.8%) cases, respectively. Expression of p16 was lost in 35 (92.1%) cases, equivocal in one (2.6%), and failed in 2 (5.3%), while MTAP expression was lost in 27 (71.1%) cases, retained in 10 (26.3%), and equivocal in one (2.6%). This yielded a sensitivity of 94.6% for p16 and 73.0% for MTAP in detecting CDKN2A homozygous deletion through immunohistochemistry. MTAP expression was lost in the 2 cases with failed p16 staining (combined sensitivity of 100%). Our findings demonstrate that combined p16 and MTAP immunostains correctly detect CDKN2A homozygous deletion in PXA, while MTAP expression alone shows reduced sensitivity.
Current Clinical Concepts: Rehabilitation of Thoracic Outlet Syndrome
Hock, Greg, Johnson, Andrew, Papa, Cassidy, Johnson, Andrew, Barber, Patrick, Johnson, Andrew

Journal of Athletic Training | July 24, 2024 | Volume: 59 | Issue: 7 | Pages: 683-695

10.4085/1062-6050-0138.22 | PMID 39048118 Get It

Thoracic outlet syndrome (TOS) involves inconsistent symptoms, presenting a challenge for medical providers to diagnose and treat. Thoracic outlet syndrome is defined as a compression injury to the brachial plexus, subclavian artery or vein, or axillary artery or vein occurring between the cervical spine and upper extremity. Three common subcategories are now used for clinical diagnosis: neurogenic, arterial, and venous. Postural position and repetitive motions such as throwing, weightlifting, and manual labor can lead to symptoms. Generally, TOS is considered a diagnosis of exclusion for athletes due to the poor accuracy of clinical testing, including sensitivity and specificity. Thus, determining a definitive diagnosis and reporting injury is difficult. Current literature suggests there is not a gold standard diagnostic test. Rehabilitation has been shown to be a vital component in the recovery process for neurogenic TOS and for arterial TOS and venous TOS in postoperative situations.
Primary cilia mediate skeletogenic BMP and Hedgehog signaling in heterotopic ossification
He, Kai , Jiang, Heng , Li, Weijun , Toutounchi, Saman , Ma, Xiaoyu , Baehr, Wolfgang , Pignolo, Robert J. , Ling, Kun , Wang, Haitao , Hu, Jinghua , Ma, Xiaoyu , Zhou, Xuhui , Wang, Haitao , Hu, Jinghua , He, Kai , Huang, Yan , Wu, Jianfeng

Science Translational Medicine | July 24, 2024 | Volume: 16 | Issue: 757 | Pages: No page available

10.1126/scitranslmed.abn3486 | PMID 39047114 Get It

Heterotopic ossification (HO), defined as the formation of extraskeletal bone in muscle and soft tissues, is a diverse pathological process caused by either genetic mutations or inciting trauma. Fibrodysplasia ossificans progressiva (FOP) is a genetic form of HO caused by mutations in the bone morphogenetic protein (BMP) type I receptor gene activin A receptor type 1 ( ACVR1 ). These mutations make ACVR1 hypersensitive to BMP and responsive to activin A. Hedgehog (Hh) signaling also contributes to HO development. However, the exact pathophysiology of how skeletogenic cells contribute to endochondral ossification in FOP remains unknown. Here, we showed that the wild-type or FOP-mutant ACVR1 localized in the cilia of stem cells from human exfoliated deciduous teeth with key FOP signaling components, including activin A receptor type 2A/2B, SMAD family member 1/5, and FK506-binding protein 12kD. Cilia suppression by deletion of intraflagellar transport 88 or ADP ribosylation factor like GTPase 3 effectively inhibited pathological BMP and Hh signaling, subdued aberrant chondro-osteogenic differentiation in primary mouse or human FOP cells, and diminished in vivo extraskeletal ossification in Acvr1 Q207D , Sox2-Cre ; Acvr1 R206H/+ FOP mice and in burn tenotomy–treated wild-type mice. Our results provide a rationale for early and localized suppression of cilia in affected tissues after injury as a therapeutic strategy against either genetic or acquired HO.
Dapagliflozin and Right Ventricular–Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction
Reddy, Yogesh N.V. , Carter, Rickey E. , Sorimachi, Hidemi, Omar, Massar , Popović, Dejana , Jensen, Michael D. , Alogna, Alessio , Nishimura, Rick , Carter, Rickey E , Omar, Massar , Borlaug, Barry A.

JAMA Cardiology | July 24, 2024 | Volume: 9 | Issue: 9 | Pages: 843

10.1001/jamacardio.2024.1914 | PMID 39046727 Get It

ImportanceIncreases in pulmonary capillary wedge pressure (PCWP) during exercise reduce pulmonary artery (PA) compliance, increase pulsatile right ventricular (RV) afterload, and impair RV-PA coupling in patients with heart failure with preserved ejection fraction (HFpEF). The effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin on pulmonary vascular properties and RV-PA coupling are unknown.ObjectiveTo test the effect of dapagliflozin on right ventricular performance and pulmonary vascular load during exertion in HFpEF.Design, Setting, and ParticipantsEvaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction (CAMEO-DAPA) randomized clinical trial demonstrated improvement in PCWP at rest and exercise over 24 weeks with dapagliflozin compared with placebo with participants recruited between February 2021 and May 2022. This secondary analysis evaluates the effects of dapagliflozin on pulsatile pulmonary vascular load and RV-PA coupling using simultaneous echocardiography and high-fidelity invasive hemodynamic testing with exercise. This was a single-center study including patients with hemodynamically confirmed HFpEF with exercise PCWP of 25 mm Hg or greater.InterventionsDapagliflozin or placebo for 24 weeks.Main Outcomes and MeasuresPulsatile pulmonary vascular load (PA compliance and elastance) and right ventricular performance (PA pulsatility index, RV systolic velocity [s′]/PA mean) during rest and exercise.ResultsAmong 37 randomized participants (mean [SD] age, 67.4 [8.5] years; 25 female [65%]; mean [SD] body mass index, 34.9 [6.7]; calculated as weight in kilograms divided by height in meters squared), there was no effect of dapagliflozin on PA loading or RV-PA interaction at rest. However, with exercise, dapagliflozin improved PA compliance (placebo-corrected mean difference, 0.57 mL/mm Hg; 95% CI, 0.11-1.03 mL/mm Hg; P = .02) and decreased PA elastance (stiffness; −0.17 mm Hg/mL; 95% CI, −0.28 to −0.07 mm Hg/mL; P = .001). RV function during exercise improved, with increase in PA pulsatility index (0.33; 95% CI, 0.08-0.59; P = .01) and increase in exercise RV s′ indexed to PA pressure (0.09 cm·s−1/mm Hg; 95% CI, 0.02-0.16 cm·s−1/mm Hg; P = .01). Improvements in pulsatile RV load and RV-PA coupling were correlated with reduction in right atrial (RA) pressure (PA elastance Pearson r = 0.55; P =.008; RV s′/PA elastance Pearson r = −0.60; P =.002) and PCWP (PA elastance Pearson r = 0.58; P <.001; RV s′/PA elastance Pearson r = −0.47; P = .02). Dapagliflozin increased resistance-compliance time (dapagliflozin, median [IQR] change, 0.06 [0.03-0.15] seconds; placebo, median [IQR] change, 0.01 [−0.02 to 0.05] seconds; P =.046), resulting in higher PA compliance for any exercise pulmonary vascular resistance.Conclusions and RelevanceResults of this randomized clinical trial reveal that treatment with dapagliflozin for 24 weeks reduced pulsatile pulmonary vascular load and enhanced dynamic RV-PA interaction during exercise in patients with HFpEF, findings that are related to the magnitude of PCWP reduction. Benefits on dynamic right ventricular–pulmonary vascular coupling may partially explain the benefits of SGLT2 inhibitors in HFpEF.Trial RegistrationClinicalTrials.gov Identifier: NCT04730947
Shifting the Cancer Screening Paradigm: Developing a Multi-Biomarker Class Approach to Multi-Cancer Early Detection Testing
Ebbert, Jon O. , Taylor, William R. , Marinac, Catherine R. , Choudhry, Omair A., Rego, Seema P., Beidelschies, Michelle , Ebbert, Jon O , Marinac, Catherine R , Choudhry, Omair A , Beidelschies, Michelle A , Kisiel, John B. , Taylor, William R., Beer, Tomasz M.

Life | July 24, 2024 | Volume: 14 | Issue: 8 | Pages: 925

10.3390/life14080925 | PMID 39202669 Get It

Guideline-recommended screening programs exist for only a few cancer types. Although all these programs are understood to lead to reductions in cancer-related mortality, standard-of-care screening tests vary in accuracy, adherence and effectiveness. Recent advances in high-throughput technologies and machine learning have facilitated the development of blood-based multi-cancer cancer early detection (MCED) tests. MCED tests are positioned to be complementary to standard-of-care screening and they may broaden screening availability, especially for individuals who are not adherent with current screening programs and for individuals who may harbor cancers with no available screening options. In this article, we outline some key features that should be considered for study design and MCED test development, provide an example of the developmental pathway undertaken for an emerging multi-biomarker class MCED test and propose a clinical algorithm for an imaging-based diagnostic resolution strategy following MCED testing.
Specific Biomarkers in Spinocerebellar Ataxia Type 3: A Systematic Review of Their Potential Uses in Disease Staging and Treatment Assessment
Soto‐Piña, Alexandra Estela , Pulido-Alvarado, Caroline C., Dulski, Jarosław , Wszołek, Zbigniew K. , Magaña, Jonathan J. , Wszolek, Z.K. , Soto-Piña, Alexandra E., Dulski, Jaroslaw

International Journal of Molecular Sciences | July 24, 2024 | Volume: 25 | Issue: 15 | Pages: 8074

10.3390/ijms25158074 | PMID 39125644 Get It

Spinocerebellar ataxia type 3 (SCA3) is the most common type of disease related to poly-glutamine (polyQ) repeats. Its hallmark pathology is related to the abnormal accumulation of ataxin 3 with a longer polyQ tract (polyQ-ATXN3). However, there are other mechanisms related to SCA3 progression that require identifying trait and state biomarkers for a more accurate diagnosis and prognosis. Moreover, the identification of potential pharmacodynamic targets and assessment of therapeutic efficacy necessitates valid biomarker profiles. The aim of this review was to identify potential trait and state biomarkers and their potential value in clinical trials. Our results show that, in SCA3, there are different fluid biomarkers involved in neurodegeneration, oxidative stress, metabolism, miRNA and novel genes. However, neurofilament light chain NfL and polyQ-ATXN3 stand out as the most prevalent in body fluids and SCA3 stages. A heterogeneity analysis of NfL revealed that it may be a valuable state biomarker, particularly when measured in plasma. Nonetheless, since it could be a more beneficial approach to tracking SCA3 progression and clinical trial efficacy, it is more convenient to perform a biomarker profile evaluation than to rely on only one.
Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma
Cheraghlou, Shayan , Christensen, Sean R. , Walker, Joanna, Ferrándiz‐Pulido, Carla , Bibee, Kristin , Carter, Joi B., Samie, Faramarz H. , Carroll, Bryan T. , Vidimos, Allison T. , Baum, Christian L. , Leitenberger, Justin J. , Jambusaria‐Pahlajani, Anokhi , Ruiz, Emily S. , Carr, David R. , Shahwan, Kathryn T. , Stevenson, Mary L. , Bordeaux, Jeremy S. , Srivastava, Divya , Patel, Vishal Anil , Carucci, John A. , Carr, David R.

JAMA Dermatology | July 24, 2024 | Volume: 160 | Issue: 9 | Pages: 989

10.1001/jamadermatol.2024.2242 | PMID 39046711 Get It

ImportanceCutaneous squamous cell carcinoma (CSCC) is the second most common malignant disease in the US. Although it typically carries a good prognosis, a subset of CSCCs are highly aggressive, carrying regional and distant metastatic potential. Due to its high incidence, this aggressive subset is responsible for considerable mortality, with an overall annual mortality estimated to equal or even surpass melanoma. Despite this morbidity, CSCC is excluded from national cancer registries, making it difficult to study its epidemiology and outcomes. Therefore, the bulk of the CSCC literature is composed of single-center and multi-institutional retrospective cohort analyses. Given variations in reporting measures and analyses in these studies, interpretability between studies and the ability to pool results are limited.ObjectiveTo define standardized reporting measures for retrospective CSCC studies.FindingsAn expert panel was convened to determine standardized guidelines for recording and analyzing retrospective CSCC data. A total of 13 dermatologists and dermatologic surgeons with more than 5 years of posttraining experience and considerable experience with performing CSCC outcomes research were recruited to the panel. Consensus recommendations were achieved for CSCC retrospective study reporting measures, definitions, and analyses.Conclusions and RelevanceThe recommendations in this report present the potential to standardize future CSCC retrospective studies. With such standardization, future work may have greater interstudy interpretability and allow for pooled analyses.
Providing Performance Feedback and Patient Outcome Follow-Up to Emergency Medical Services (EMS) is Associated with Subsequent Improved Clinical Performance
McGuire, Sarayna S. , Klassen, Aaron B. , Luke, Anuradha, Rentz, Lisa C, Liedl, Chad P., Sztajnkrycer, Matthew D. , Klassen, Aaron, Rentz, Lisa, McGuire, Sarayna S , Mullan, Aidan F.

Prehospital Emergency Care | July 24, 2024 | Volume: 29 | Issue: 5 | Pages: 632-638

10.1080/10903127.2024.2383323 | PMID 39047172 Get It

Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer’s disease
Josephs, Keith A. , Tosakulwong, Nirubol , Weigand, Stephen D. , Graff-Radford, Jonathan, Schwarz, Christopher G. , Senjem, Matthew L. , Machulda, Mary M. , Kantarci, Kejal , Knopman, David S. , Nguyen, Aivi T. , Reichard, R. Ross , Petersen, Ronald C. , Lowe, Val J. , Jack, Clifford R. , Whitwell, Jennifer L., Knopman, David S. , Nguyen, Aivi T , Dickson, Dennis W , Petersen, Ronald C , Jack, Clifford R , Schwarz, Christopher G , Senjem, Matthew L , Kantarci, Kejal , Machulda, Mary M , Graff‐Radford, Jonathan , Dickson, Dennis W. , Whitwell, Jennifer

Science Translational Medicine | July 24, 2024 | Volume: 16 | Issue: 757 | Pages: No page available

10.1126/scitranslmed.ado8076 | PMID 39047115 Get It

[ 18 F]-Flortaucipir positron emission tomography (PET) is considered a good biomarker of Alzheimer’s disease. However, it is unknown how flortaucipir is associated with the distribution of tau across brain regions and how these associations are influenced by amyloid-β. It is also unclear whether flortaucipir can detect tau in definite primary age–related tauopathy (PART). We identified 248 individuals at Mayo Clinic who had undergone [ 18 F]-flortaucipir PET during life, had died, and had undergone an autopsy, 239 cases of which also had amyloid-β PET. We assessed nonlinear relationships between flortaucipir uptake in nine medial temporal and cortical regions, Braak tau stage, and Thal amyloid-β phase using generalized additive models. We found that flortaucipir uptake was greater with increasing tau stage in all regions. Increased uptake at low tau stages in medial temporal regions was only observed in cases with a high amyloid-β phase. Flortaucipir uptake linearly increased with the amyloid-β phase in medial temporal and cortical regions. The highest flortaucipir uptake occurred with high Alzheimer’s disease neuropathologic change (ADNC) scores, followed by low-intermediate ADNC scores, then PART, with the entorhinal cortex providing the best differentiation between groups. Flortaucipir PET had limited ability to detect PART, and imaging-defined PART did not correspond with pathologically defined PART. In summary, spatial patterns of flortaucipir mirrored the histopathological tau distribution, were influenced by the amyloid-β phase, and were useful for distinguishing different ADNC scores and PART.